一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

belatacept

belatacept Struktur
706808-37-9
CAS-Nr.
706808-37-9
Englisch Name:
belatacept
Synonyma:
belatacept;Research Grade Belatacept;Research Grade Belatacept (DHE03402)
CBNumber:
CB51508591
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

belatacept Eigenschaften

Aggregatzustand
Solid
Farbe
White to off-white

Sicherheit

belatacept Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Belatacept is an immunosuppressive that was approved by the U.S. FDA for prophylactic prevention of rejection in kidney transplant recipients. Belatacept, which selectively blocks T cell costimulation, provides an alternative to the calcineurin inhibitors, which are associated with adverse effects on renal function as well as cardiovascular and metabolic parameters. T-cell activation by antigen-presenting cells (APCs) requires a costimulatory signal in addition to the signal mediated by interaction of the T-cell receptor and MHC-bound peptide antigen. Belatacept can block that second signal by binding to APC costimulatory surface proteins CD80 and CD86 to inhibit their interaction with the T-cell signaling molecule CD28. Belatacept is a recombinant protein comprising a hinge-region modified (to reduce Fc receptor binding) carboxylterminal human IgG1 Fc domain fused to a modified extracellular domain of human CTLA-4 that includes two amino acid substitutions in the ligand-binding site. As a result of this modification, belatacept binds more tightly to CD80 and CD86 than the parent molecule abatacept (Orencia, FDA approved for treatment of adult RA and juvenile idiopathic arthritis), from which its structure is derived. CTLA-4 is a T-cell negative signaling molecule that is structurally related to CD28 and shares its two ligands. While belatacept incorporates CTLA-4 sequences to bind CD80 and CD86, the immunosuppressive activity of the drug suggests that its principal mechanism of action is blockade of CD28-mediated T-cell activation.

Verwenden

Prevention of allograft rejection in recipients of solid organ transplants; prevention of graft-vs-host disease following bone marrow transplantation; treatment of autoimmune diseases and conditions such as rheumatoid arthritis and Type 1 diabetes.

belatacept Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


belatacept Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 8)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
BOC Sciences
16314854226; +16314854226
inquiry@bocsci.com United States 19853 58
Shanghai YuanYe Biotechnology Co., Ltd. 021-61312847; 18021002903
3008007409@qq.com China 89686 60
Wuhan Chemstan Biotechnology Co., Ltd. 027-65317797 15926423062
422450190@qq.com China 10308 58
Biolab Reagents 027-65279366 18108604356
products@biolabreagent.com China 9865 58
TargetMol Chemicals Inc. 15002134094
marketing@targetmol.cn China 29855 58
Atagenix Laboratories 027-87008169 17762441161
info@atagenix.com China 9998 58
AntibodySystem Laboratories SAS --
support@antibodysystem.com China 6738 58
Guangzhou Kati Biotechnology Co., Ltd. --
CHINA 6598 58

  • belatacept
  • Research Grade Belatacept (DHE03402)
  • Research Grade Belatacept
  • 706808-37-9
Copyright 2019 ? ChemicalBook. All rights reserved
庆阳市| 龙海市| 汾阳市| 汉川市| 会泽县| 唐河县| 灵寿县| 恩平市| 奇台县| 满洲里市| 高雄县| 宜宾县| 霍城县| 郎溪县| 郎溪县| 内江市| 昭苏县| 墨江| 龙泉市| 广水市| 那曲县| 普定县| 武安市| 门源| 山东| 潞西市| 蕉岭县| 思南县| 固镇县| 中山市| 邵阳县| 隆昌县| 孙吴县| 疏勒县| 合江县| 兰考县| 石城县| 玉溪市| 白城市| 吉水县| 谷城县|